RECURRENT RESPIRATORY PAPILLOMATOSIS
Clinical trials for RECURRENT RESPIRATORY PAPILLOMATOSIS explained in plain language.
Never miss a new study
Get alerted when new RECURRENT RESPIRATORY PAPILLOMATOSIS trials appear
Sign up with your email to follow new studies for RECURRENT RESPIRATORY PAPILLOMATOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Yale tests drug combo for rare, recurring throat and lung growths
Disease control Recruiting nowThis early-phase study is testing whether a combination of two existing cancer drugs can help control a rare condition where HPV causes recurring wart-like growths in the airways and lungs. The trial will enroll about 20 adults to see if the drugs are safe and can shrink the grow…
Matched conditions: RECURRENT RESPIRATORY PAPILLOMATOSIS
Phase: EARLY_PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First-in-Human trial tests custom vaccine for debilitating throat condition
Disease control Recruiting nowThis early-stage study is testing a new, personalized vaccine made from a patient's own immune cells. It aims to see if the vaccine is safe and can trigger an immune response against the virus that causes recurrent, non-cancerous growths in the throat. The study will enroll 9 adu…
Matched conditions: RECURRENT RESPIRATORY PAPILLOMATOSIS
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Second chance treatment tested for rare throat growths
Disease control Recruiting nowThis study is testing whether a second round of treatment with an experimental therapy called zopapogene imadenovec (Zopa) can help adults with recurrent respiratory papillomatosis (RRP), a condition causing wart-like growths in the throat and airways. Researchers will track how …
Matched conditions: RECURRENT RESPIRATORY PAPILLOMATOSIS
Phase: PHASE4 • Sponsor: Precigen, Inc • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC